Litcius/Paper detail

CLL-115 First Interim Analysis of ALPINE Study: Results of a Phase 3 Randomized Study of Zanubrutinib vs Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Jennifer R. Brown, Peter Hillmen, Barbara Eichhorst, Nicole Lamanna, Susan O’Brien, Constantine S. Tam, Lugui Qiu, Maciej Kaźmierczak, Keshu Zhou, Martin Šimkovič, Jiřı́ Mayer, Amanda Gillespie-Twardy, Mazyar Shadman, Alessandra Ferrajoli, Peter Ganly, Robert Weinkove, Tommi Salmi, Kenneth K. Wu, William Novotny, Wojciech Jurczak

2022Clinical Lymphoma Myeloma & Leukemia12 citationsDOI

Topics & Concepts

IbrutinibMedicineInternal medicineInterim analysisClinical endpointOncologyChronic lymphocytic leukemiaPhases of clinical researchClinical trialLeukemiaChronic Lymphocytic Leukemia Research
CLL-115 First Interim Analysis of ALPINE Study: Results of a Phase 3 Randomized Study of Zanubrutinib vs Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | Litcius